Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04841629 · ClinicalTrials.gov registry record · NA
Perception & Acceptability of a Cervical Cancer Prevention Prebiotic Device
A NA study of Sensory Perceptual Characteristics and User Acceptability of Gel Delivery System, sponsored by Glyciome.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT04841629: Completed NA study of Sensory Perceptual Characteristics and User Acceptability of Gel Delivery System, sponsored by Glyciome.
NCT04841629 is a NA study of Sensory Perceptual Characteristics and User Acceptability of Gel Delivery System that has completed, run by Glyciome. The registered enrollment target is 42 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04841629, a NA study of Sensory Perceptual Characteristics and User Acceptability of Gel Delivery System, has completed, sponsored by Glyciome.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
PreBioGyn will be compared to market leading vaginal pH buffering gels using established forearm test methods associated with vaginal lubricity sensation in 42 women. Women will also rate each gel for smell and appearance using established methods. The PreBioGyn gel enclosure and intravaginal applicator design will be evaluated for: look and feel, ability to prepare for dosing, ability to expulse dose, and likelihood of future use by subjects. Open-ended feedback on the gel and applicator will occur to gather contributions for each product.
Conditions Studied
Interventions
- OTHER PreBioGyn Gel
- OTHER Trimosan Gel
- OTHER RepHresh Gel
Study Locations (2)
Massachusetts
- Brigham and Women'S Hospital - Boston
Other
- University of Puerto Rico Medical Sciences - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-02-24 |
| Est. Completion | 2022-11-28 |
| Phase | NA |
What the finished NCT04841629 record still lists
NCT04841629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Sensory Perceptual Characteristics appearing as the primary indexed condition, and to 3 interventions - of which PreBioGyn Gel is the first listed.
NCT04841629 reports a single indexed study location in Massachusetts, Other.
Frequently Asked Questions
What is clinical trial NCT04841629 about?
NCT04841629 is a clinical study titled "Perception & Acceptability of a Cervical Cancer Prevention Prebiotic Device". PreBioGyn will be compared to market leading vaginal pH buffering gels using established forearm test methods associated with vaginal lubricity sensation in 42 women. Women will also rate each gel for smell and appearance using established methods. The PreBioGyn gel enclosure and intravaginal applic...
What is the current status of trial NCT04841629?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2022-02-24. Estimated completion is 2022-11-28.
What conditions does trial NCT04841629 study?
This clinical trial studies the following conditions: Sensory Perceptual Characteristics, User Acceptability of Gel Delivery System.
What interventions are being tested in trial NCT04841629?
The interventions under investigation include: PreBioGyn Gel (OTHER), Trimosan Gel (OTHER), RepHresh Gel (OTHER).
Who is sponsoring clinical trial NCT04841629?
This trial is sponsored by Glyciome, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04841629 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04841629's enrollment target sits among peer trials
42 1436th of 2000 higher than 555 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI